medigraphic.com
Órgano Oficial de la Asociación Mexicana de Infectología Pediátrica y la SLIPE.

2011, Number 98

<< Back Next >>

Rev Enfer Infec Pediatr 2011; 24.25 (98)

Polymyxins in the era of multidrug resistance

Coria LJJ, Morayta RA, Gutiérrez MY

Language: Spanish
References: 28
Page: 66-70
PDF size: 156.21 Kb.


ABSTRACT

Background: In recent years, the effectiveness of various medical and non-medical procedures a patient receives in a critical intensive care unit, is overshadowed by the emergence of multidrug-resistant pathogens, especially when associated with infections related with health care (also known as nosocomial). Their existence, limits the expectations of the therapeutic options available to hospitals that serve these patients and generates combinations of treatments called «salvage therapy or rescue »
Objective: To review the effects and benefits of colistin (polymyxin E).
Material and methods: A review of recent published articles that evaluate the administration of colistin (polymyxin E) in patients with serious infections associated with multidrug agents.
Conclusions: There is a large ammount of literature that considers the return of colistin (polymyxin-E) treatment options not as an initial choice, but as a rational appeal for special cases caused by Gram negative.


REFERENCES

  1. Falagas ME, Kasiakou SK. Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram- Negative Bacterial Infections. CID 2005;40:1333-1341.

  2. Nation RL, Turnidge JD, Milne RW, Coulthard K, Rainer CR, et al. Colistin: The re-emerging ant biotic for multidrugresistant Gram-negative bacterial infections. Lancet Infec Dis 2006;6:589-601.

  3. Peleg AY, Hooper DC. Hospital-Acquired Infections Due to Gram-Negative Bacteria. NEJM 2010;362:1804-1813.

  4. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare- associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996-1011.

  5. National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. [Erratum], Infect Control Hosp Epidemiol 2009;30:107.

  6. Fuente: Notificación de los SESA a EPINOSO o Plataforma del SINAVE. DGE (RHOVE). Reportes preliminares 2010.

  7. Newton BA. The properties and mode of action of polymyxins. Bacteriol Rev 1956;20:14-27.

  8. Schindler M, Osborn MJ. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 1979;18:4425-4430.

  9. Bengoechea JA, Skurnik M. Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia. Mol Microbiol 2000;37:67-80.

  10. Denton M, Kerr K, Mooney L, et al. Transmission of colistinresistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol 2002;34:257-261.

  11. Bouallegue-Godet O, Ben SY, Fabre I, et al. Nosocomial outbreak caused by Salmonella enterica serotype Livingstone producing CTX-M-27 extended spectrum beta-lactamase in a neonatal unit in Sousse Tunisia. J Clinic Microbiol 2005;43:1037-1044.

  12. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005;41:848-854.

  13. Bishara J, Livne G, Ashkenazi S, et al. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Isr Med Asoc J 2005;7:298-301.

  14. Jarvis WR. The Lowbury Lecture; the United States approach to strategies in the battle against healthcare-associated infections, 2006: transitioning from bench-marking to zero tolerate and clinician accountability. J Hosp Infect 2007;65:Suppl2:3-9.

  15. El Sholh AA, Alhajhusain A. Update on the treatment of P aeruginosa pneumonia. JAC 2009;64:229-238.

  16. Mastoraki A, Douka E, Kriaras J, Stravopodis G, Manoli H & Geroulanos S. P aeruginosa Susceptible Only to Colistin in Intensive Care Unit Patients. Surg Infect 2008;9(2):153-159.

  17. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and Safety of Colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant P aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Inter J Infect Dis 2007;11:402-406.

  18. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008;13(47):1945.

  19. Jacobsen SM, Stickler DJ, Mobley HL, Shirtliff ME. Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev 2008;21:26-59.

  20. Michalopoulus AS, Tsiodras S, Rellos K, Mentzelopoulus S, Falagas ME. Colistin treatment in patients with ICUaquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old ant biotic. Clin Microbiol Infect 2005;11:115-121.

  21. Michalopoulus AS, Kasiakou S, Rosmarakis E, Falagas ME. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand J Infect Dis 2005;37:142-145.

  22. Falagas ME, Risos M, Bliziotis IA, Rellos K, Kasiakou SK, et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005;5:1.

  23. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrugresistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-1111.

  24. Markou N, Apostolakos H, Koumoudio C, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003;7;R78-R83.

  25. Gamacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilador-associated pneumoniae (VAP) with intravenous colistin: a comparison with imipenemsusceptible VAP. Clin Infect Dis 2003;36:1111-1118.

  26. Higgins PG, Dammhayn C, Hackel M, Seiferet H. Global Spreads of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010;65:233-238.

  27. Linden P, Kusne S, Coley K, Fontes P, Kramer D, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003;37:E154-E160.

  28. Salinas CM, Hernández AL, Oropeza R, Olvera CG, Poblano MM, et al. Colistín en el tratamiento de infecciones por Pseudomonas aeruginosa multidrogorresistente. Asoc Mex Med Crit XXIV;(4):173-177.




2020     |     www.medigraphic.com